IPR Settlement & Competition Law - What’s New?

Introduction

A common area for intellectual property rights (‘IPR’) litigation concerns the situation where one party alleges infringement of its IPR, and the defendant challenges the validity of that IPR.

Many such disputes have been resolved by settlement agreements, but such arrangements can themselves raise their own competition concerns.

Competition law cases in the pharmaceutical sector since the European Commission’s final report have tended to focus on settlement agreements between originators and originators.

This has also been an area of antitrust scrutiny in the USA.

Recent cases and litigation suggest a renewed focus on competition concerns in settlement agreements with implications in and beyond the pharmaceutical sector.

This new webinar provides an exploration of how settlements concluded in the context of IPR licensing can raise competition law compliance issues.

What You Will Learn

This webinar will cover the following:

• A reminder of how UK and EU competition law affects settlement licensing agreements
• Spotlight on patent licensing and ‘pay for delay’ cases in the UK, EU, and USA
• Update on recent high-profile UK and EU cases including Laboratories Servier and GSK
• Practical case study
• Top tips for risk management

This webinar was recorded on 17th February 2022